# EDGAR Filing Document

**Accession Number:** 0001616543
**File Stem:** 0001104659-23-032796
**Filing Date:** 2023-3
**Character Count:** 20233
**Document Hash:** c72ca74797c0c5aa2cdddaad1e414ba7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-032796.hdr.sgml**: 20230315

**ACCESSION NUMBER**: 0001104659-23-032796

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230315

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230315

**DATE AS OF CHANGE**: 20230315

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Senseonics Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001616543
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823]
- **IRS NUMBER:** 471210911
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37717
- **FILM NUMBER:** 23735505

**BUSINESS ADDRESS:**
- **STREET 1:** 20451 SENECA MEADOWS PARKWAY
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20876
- **BUSINESS PHONE:** (301) 515-7260

**MAIL ADDRESS:**
- **STREET 1:** 20451 SENECA MEADOWS PARKWAY
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20876

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASN Technologies, Inc.
- **DATE OF NAME CHANGE:** 20140813

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **March 15, 2023**

---

| |
|:---|
| **SENSEONICS HOLDINGS, INC.** |
| &nbsp;&nbsp;(Exact Name of Registrant as Specified in its Charter) |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**001-37717** | &nbsp;&nbsp;**47-1210911** |
| (State or Other <br> Jurisdiction of Incorporation) | &nbsp;&nbsp;(Commission File Number) | &nbsp;&nbsp;(IRS Employer<br> Identification No.) |

---

---

| |
|:---|
| &nbsp;&nbsp;**20451 Seneca Meadows Parkway<br> Germantown, MD 20876-7005** |
| (Address of Principal Executive Office) (Zip Code) |

---

Registrant's telephone number, including area code: **(301) 515-7260**

**<u>Not Applicable</u>**

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2 below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock | SENS | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 2.02. Results of Operations and Financial Condition.**

On March 15, 2023, Senseonics Holdings, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2022, as well as information regarding a conference call to discuss these financial results and the Company's recent corporate highlights and outlook. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by this reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

**Item 9.01. Financial Statements and Exhibits.**

(d)*Exhibits.*

---

| | |
|:---|:---|
| Exhibit |  |
| Number | Description |
| [99.1](tm239630d1_ex99-1.htm) | [Press Release of Senseonics Holdings, Inc. dated March 15, 2023.](tm239630d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 15, 2023 | **SENSEONICS HOLDINGS, INC.** | **SENSEONICS HOLDINGS, INC.** |
|  | By: | /s/ *Rick Sullivan* |
|  | Name: | Rick Sullivan |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm239630d1_ex99-1img001.jpg)

**SENSEONICS HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS**

*Senseonics, PHC Holdings Corporation and Ascensia Diabetes Care Joint Eversense CGM Virtual Analyst and Investor Event to begin March 15<sup>th</sup>, 2023 at 6:30pm ET*

**GERMANTOWN, MD, March 15, 2023** —Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2022.

**Recent Highlights & Accomplishments:**

· Generated fourth quarter 2022 revenue of $5.6 million and full year 2022 revenue of $16.4 million.

· Achieved full year of gross profit for the first time in the Company's history.

· Accelerated the 365-day sensor program by fully enrolling the ENHANCE trial adult cohort with the 365-day sensor configuration in Q3 22
and advanced the program further by receiving FDA IDE approval for the enrollment of a pediatric cohort.

· Expanded the Nurse Practitioner Group partnership, focused on increasing U.S. patient access to E3 by providing additional convenient
in-office and at-home sensor insertion options, into over 20 total geographic markets to date.

· CMS Calendar Year 2023 Medicare Physician Fee Schedule initiated updates to national pricing that accounts for the longer 6-month
sensor for all three CPT codes used for the Eversense E3 system.

· Closed additional financing from PHC Holdings consisting of a $15 million equity investment in Senseonics on March 13, 2023 and
 concurrently signed an agreement to exchange the $35 million convertible note for equity.

"2022 was a year of notable progress in building the Eversense business, with FDA approval, CE mark and global launch of the E3 system and the acceleration of a pivotal trial for a 365-day sensor configuration that we plan will also support both ICGM and a pediatric indication," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "Together with establishing the Nurse Practitioner Group partnership, expanding E3 coverage from Medicare and commercial payers, and coordinating expansion of the Ascensia U.S. salesforce, we have further advanced important initiatives to help bring the benefits of Eversense long-term implantable CGM to growing numbers of patients."

**Fourth Quarter 2022 Results:**

Total revenue for the fourth quarter of 2022 was $5.6 million, compared to $4.0 million for the fourth quarter of 2021. U.S. revenue was $3.6 million in the fourth quarter of 2022, compared to $0.7 million in the prior year period, and revenue outside the U.S. was $2.0 million in the fourth quarter of 2022, compared to $3.3 million in the prior year period.

Fourth quarter 2022 gross profit of $0.6 million increased from a gross loss of $0.5 million in the fourth quarter of 2021.

Fourth quarter 2022 research and development expenses increased by $4.0 million year-over-year, to $11.6 million. The increase was primarily due to investments in product development and clinical trials for next generation technologies.

Fourth quarter 2022 selling, general and administrative expenses increased by $2.0 million year-over-year, to $7.8 million. The increase was primarily the result of increased payroll and stock-based compensation expense.

Net income was $11.6 million, or $.02 per share, in the fourth quarter of 2022 compared to net income of $84.4 million, or $.19 per share, in the fourth quarter of 2021. Net income decreased by $72.8 million due to the non-cash accounting for embedded derivatives and fair value adjustments.

![](tm239630d1_ex99-1img001.jpg)

**Full Year 2022 Results:**

Total revenue for 2022 was $16.4 million compared to total revenue of $13.7 million in 2021. U.S. revenue was $7.5 million in 2022 versus $2.6 million in 2021. Revenue outside the U.S. was $8.9 million in 2022 versus $11.1 million in 2021.

Gross profit for 2022 of $2.7 million increased from a gross loss of ($0.8) million in the prior year.

Research and development expenses for 2022 increased by $12.5 million year-over-year, to $39.7 million. The increase was primarily due to investments in product development and clinical trials for next generation technologies.

Sales and marketing and general and administrative expenses for 2022 increased by $2.5 million year-over-year, to $31.6 million. The increase was primarily the result of increased payroll and stock-based compensation expense.

Net income was $142.1 million, or $.30 per share, in 2022, compared to a net loss of ($302.5) million, or ($0.72) per share, in 2021. Net income increased by $444.6 million due to a $456.0 million decrease to other expenses primarily related to the accounting for embedded derivatives and fair value adjustments, partially offset by an increase in operating expenses.

As of December 31, 2022, cash, cash equivalents, short and long-term investments were $156.3 million and outstanding indebtedness was $104.0 million.

**2023 Financial Outlook**

Global net revenue to Senseonics for the full year 2023 is expected to be in the range of $20 million to $24 million representing growth of 22% to 46% compared to 2022.

**Investor and Analyst Day Webcast Information:**

Senseonics is scheduled to host a joint virtual analyst and investor event alongside PHC Holdings Corporation, the parent company of Senseonics' global commercial partner, Ascensia Diabetes Care, tonight, on Wednesday, March 15, 2023 at 6:30pm ET. The live and recorded webcast will be available on Senseonics Holdings, Inc. website at <u>www.senseonics.com</u> by navigating to "Investor Relations" and then "Events & Publications" page.

The event will include presentations from PHC Holdings Corporation and Ascensia Diabetes Care on the commercial partnership initiatives and clinical integration of Eversense and presentations from Senseonics on the Eversense technology portfolio, R&D roadmap, the fourth quarter and full year 2022 financial results announced here and Senseonics' near-term financial guidance.

**About Senseonics**

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense<sup>®</sup>, Eversense<sup>®</sup> XL and Eversense<sup>®</sup> E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

![](tm239630d1_ex99-1img001.jpg)

**Forward Looking Statements**

Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue projections under "2023 Financial Outlook," statements about the commercial launch of Eversense<sup>®</sup> E3, statements regarding increasing patient access and adoption, statement regarding advancing development programs, and other statements containing the words "believe," "expect," "intend," "may," "projects," "will," "planned," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the commercial launch of Eversense<sup>®</sup> E3 CGM system and commercial expansion of the Eversense product, uncertainties inherent in the transition of commercialization responsibilities to Ascensia Diabetes Care and its commercial initiatives, uncertainties inherent in collaborating with a new partner in the Nurse Practitioner Group and that partner's assumption of certain clinical and administrative activities, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties in the duration and severity of the COVID-19 pandemic, uncertainties inherent in the development and registration of new technology, uncertainties relating to the current economic environment, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2022 and Senseonics' other filings with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof.

**Investor Contact**

Philip Taylor

Gilmartin Group

415-937-5406

<u>Investors@senseonics.com</u>

![](tm239630d1_ex99-1img001.jpg)

**Senseonics Holdings, Inc.**

**Consolidated Balance Sheets**

**(in thousands, except for share and per share data)**

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2022** | **2021** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $35793 | $33461 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short term investments, net | 108222 | 96445 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 127 | 205 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net - related parties | 2324 | 1768 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory, net | 7306 | 6316 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 7428 | 6218 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 161200 | 144413 |
| Option |  | 239 |
| Deposits and other assets | 3108 | 1086 |
| Long term investments, net | 12253 | 51882 |
| Property and equipment, net | 1112 | 1308 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $177673 | $198928 |
| **Liabilities and Stockholders' Deficit** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $419 | $1204 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 14616 | 10667 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities, related parties | 837 | 3597 |
| &nbsp;&nbsp;&nbsp;&nbsp;Note payable, current portion, net | 15579 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivative liability, current portion | 20 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Term Loans, net |  | 2926 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 31471 | 18394 |
| Long-term debt and notes payables, net | 56383 | 59798 |
| Derivative liabilities | 52050 | 236291 |
| Option |  | 69401 |
| Other liabilities | 2689 | 579 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 142593 | 384463 |
| Commitments and contingencies |  |  |
| Preferred stock and additional paid-in-capital, subject to possible redemption: $0.001 par value per share; 12,000 shares and 0 shares issued and outstanding as of December 31, 2022 and December 31, 2021 | 37656 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total temporary equity | 37656 |  |
| Stockholders' deficit: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value per share; 900,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 479,637,138 shares and 447,282,263 shares issued and outstanding as of December 31, 2022 and December 31, 2021 | 480 | 447 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 806488 | 765215 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (678) | (212) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (808866) | (950985) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' deficit | (2576) | (185535) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities, temporary equity and stockholders' deficit | $177673 | $198928 |

---

![](tm239630d1_ex99-1img001.jpg)

**Senseonics Holdings, Inc.**

**Consolidated Statements of Operations and Comprehensive Loss**

**(in thousands, except for share and per share data)**

---

| | | | |
|:---|:---|:---|:---|
|  | **Years Ended** | **Years Ended** | **Years Ended** |
|  | **December 31,** | **December 31,** | **December 31,** |
|  | **2022** | **2021** | **2020** |
| Revenue, net | $656 | $1394 | 1368 |
| Revenue, net - related parties | 15733 | 12281 | 3581 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 16389 | 13675 | 4949 |
| Cost of sales | 13663 | 14486 | 22315 |
| Gross profit (loss) | 2726 | (811) | (17366) |
| Expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses | 39719 | 27217 | 20413 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 31634 | 29154 | 41351 |
| Operating loss | (68627) | (57182) | (79130) |
| Other income (expense), net: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 1824 | 243 | 175 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain (Loss) on fair value adjustment of option | 43745 | (53152) | (30721) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain (Loss) on extinguishment of debt and option | (101) | 330 | (21112) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on issuance of debt & other issuance costs |  |  | (12706) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (18703) | (16720) | (16167) |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt issuance costs |  |  | (1216) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain (Loss) on change in fair value of derivatives | 184221 | (174173) | (11641) |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment cost | (138) | (1647) | (2339) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expense | (102) | (173) | (311) |
| &nbsp;&nbsp;&nbsp;&nbsp; Total other income (expense), net | 210746 | (245292) | (96038) |
| Net Income (loss) | 142119 | (302474) | (175168) |
| Other comprehensive income (loss) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on marketable securities | (466) | (212) |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Total other comprehensive gain (loss) | (466) | (212) |  |
| Total comprehensive income (loss) | 141653 | (302686) | (175168) |
| Basic net income (loss) per common share | 0.30 | (0.72) | (0.77) |
| Basic weighted-average shares outstanding | 467952475 | 422321023 | 227912358 |
| Diluted net income (loss) per common share | (0.11) | (0.72) | (0.77) |
| Diluted weighted-average shares outstanding | 618205605 | 422321023 | 227912358 |

---